Tagged with AstraZeneca

Global As Big Pharma makes evermore declarations on its sustainability credentials, who are the industry’s most sustainable companies? With wildlife under severe threat from biopharmaceutical run-off, which companies are truly dedicated to change? Which are truly dedicated to equitable pay structures and promoting diversity, equity and inclusion? To answer these questions,…

UK A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in Cambridge; the GBP 17.9 million initiative to boster UK clinical trials, and Obsidian Therapeutics’ USD 160.5 million Series C funding raise.…

Spain Thanks to what AstraZeneca country president Rick Suarez called a “thriving life-science eco-system and highly-skilled talent pool,” along with Spain’s leading position in clinical trials, the British Big Pharma is intensifying its commitment to the country with a total investment of EUR 1.3 billion its new global R&D hub in…

China Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Novartis, and Takeda made it clear that Big Pharma’s interest in the country has…

UK Last year the UK-based pharma industry warned against the country’s waning competitiveness, condemning the government’s statutory scheme designed to control drug prices. UK-headquartered AstraZeneca joined the battle cry, claiming it would be choosing Ireland over Britain, a decision the company has now more than revised with a GBP 650 million…

China The biggest pharma industry stories coming out of China, including the impact of the US Biosecure act on Chinese giants WuXi AppTec and WuXi Bio; Novartis’ acquisition of SanReno Therapeutics; the first orphan drug designation for a Chinese herbal medicine-based therapy, and AstraZeneca’s new production line in Taizhou.   Eisai…

China Two leading regional pharma executives, from Eli Lilly and Boehringer Ingelheim respectively have recently moved to head up China operations; perhaps a sign that despite recent geopolitical tensions, multinational biopharma is again/still betting on the country. With innovation-friendly healthcare reforms in place, as well as measures to encourage foreign investment,…

Turkey A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in Azerbaijan; drug shortages resulting from a newly adopted currency-indexed medication supply system, and the surge in upper respiratory tract infections…

USA The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) approved no less than 55 new drugs in 2023, a number surpassing that of 2022 by almost 50 percent. While 28 rare disease treatments and five novel gene therapies got the green light, the agency also…

Portugal Sérgio Alves describes the personal and professional factors that drove his return to Portugal, where he draws on enriching experiences gained from working in various European markets. He also discusses how AstraZeneca’s COVID-19 vaccine served as a jumping-off point for more wide-ranging discussions with governmental stakeholders, and the affiliate’s positive…

United Kingdom The recent FDA decision to investigate the serious risk of patients developing new cancers after treatment with CAR-T therapies may have created some bad press around cell and gene therapies, but AstraZeneca has continued to consolidate its ambitions in the area with the acquisition of China-based cell therapy biotech, Gracell…

China The latest pharma industry and healthcare news coming out of China including AstraZeneca’s acquisition of Gracell Biotechnologies; the alarming drop in enrolment in China’s state health insurance system; Huadong Medicine/Impact Therapeutics cancer drug deal; new Changchun GeneScience Pharmaceutical R&D centre in Shanghai, and MGI Tech’s bet on Australia.   AstraZeneca,…